Tags · Compound

retatrutide

Triple GIP, GLP-1 and glucagon receptor agonist; phase 3 ongoing.

36 topics 12 solved Synonyms: reta Group: Compound

Related in this group: semaglutide · tirzepatide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues

36 topics · page 1 of 2

Topic	Participants	Replies	Views	Activity
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Compounds › Retatrutide randomised trial effect size TRIUMPH programme retatrutide Solved Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Session topic: STEP 2 ( Lancet , 2021). Please read…	+43	47	5.5k	just now
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Pharmacology › Receptor biology tirzepatide retatrutide amylin analogues long read Under review Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…	+52	57	25k	just now
What TRIUMPH is designed to answer, and why we should not pre-empt it Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Solved What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…	+4	8	142	6h
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide retatrutide randomised trial effect size preprint Solved Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…	+10	14	8.4k	16h
GIP receptor agonism and the argument about direction — does this still hold? Pharmacology › Receptor biology long read amylin analogues retatrutide Solved GIP receptor agonism and the argument about direction — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Working through the identity arithmetic…	+10	14	15k	16h
Why retatrutide discussion here is more cautious than elsewhere — one year on Compounds › Retatrutide TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+92	97	3.6k	20h
Retatrutide mass and identity: what a report should show Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with STEP 4 ( JAMA , 2021)…	+22	27	872	22h
GLP-1 receptor distribution: central and peripheral Pharmacology › Receptor biology semaglutide amylin analogues retatrutide long read Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. A documentation question rather than an analytical one. I have a…	+90	98	30k	22h
Follow-up: The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+19	23	16k	2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Compounds › Retatrutide retatrutide preprint randomised trial effect size Solved The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med…	+43	47	19k	2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide preprint retatrutide TRIUMPH programme randomised trial Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 (…	+3	7	1k	2mo
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo
Amylin receptor signalling and satiety — what changed since Pharmacology › Receptor biology tirzepatide retatrutide long read amylin analogues On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in…	+73	78	3.5k	2mo
GLP-1 receptor distribution: central and peripheral — one year on Pharmacology › Receptor biology long read retatrutide amylin analogues semaglutide GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…	+7	11	43k	3mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Pharmacology › Receptor biology retatrutide amylin analogues semaglutide Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. I would like to understand…	+57	63	1k	6mo
Retatrutide's phase 2 heart-rate signal and how to think about it Compounds › Retatrutide randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo
Follow-up: Glucagon receptor agonism in a weight-loss compound Pharmacology › Receptor biology amylin analogues long read tirzepatide retatrutide Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…	+5	9	21k	7mo
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+1	5	31k	8mo
Revisiting: GLP-1 receptor distribution: central and peripheral Pharmacology › Receptor biology amylin analogues tirzepatide retatrutide long read Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…	+61	66	15k	8mo
Follow-up: Why appetite effects are mostly central Pharmacology › Receptor biology tirzepatide retatrutide semaglutide long read Closed Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A documentation question rather than an analytical one. I have a certificate in front of me that reports a…	+86	90	61k	9mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…		4	3.7k	10mo
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
GIP receptor agonism and the argument about direction Pharmacology › Receptor biology tirzepatide long read amylin analogues semaglutide GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise…		2	867	10mo
[2026 update] What we do not know about retatrutide, listed explicitly Compounds › Retatrutide TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…	+79	83	952	11mo
Vagal afferents and the gut-brain pathway — one year on Pharmacology › Receptor biology amylin analogues long read semaglutide retatrutide Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…		2	136	11mo
Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide retatrutide effect size preprint Solved The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…	+71	80	38k	11mo
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide randomised trial preprint effect size retatrutide Solved Closed On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…	+12	16	50k	12mo
Vagal afferents and the gut-brain pathway Pharmacology › Receptor biology semaglutide tirzepatide retatrutide long read On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…	+5	9	44k	13mo
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo
Retatrutide dose escalation in the published trials Compounds › Retatrutide preprint retatrutide effect size Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…	+149	159	30k	15mo

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →